Literature DB >> 8069655

Quantification of mitochondrial DNA carrying the tRNA(8344Lys) point mutation in myoclonus epilepsy and ragged-red-fiber disease.

A Suomalainen1, P Kollmann, J N Octave, H Söderlund, A C Syvänen.   

Abstract

Myoclonus epilepsy and ragged-red-fiber syndrome (MERRF) is caused by a point mutation at nucleotide 8344 in the tRNA(Lys) gene of mitochondrial DNA. We analyzed leukocyte DNA from nine members of a large MERRF family using a new technique, solid-phase minisequencing. Quantitative analysis of the tRNA(8344Lys) mutation showed that the mutated mtDNA comprised from 9 to 72% of the total mtDNA in the leukocytes of these individuals. The minisequencing method is a promising tool for the diagnosis of MERRF. In addition to the identification of the tRNA(8344Lys) mutation, the relative amount of mutated mtDNA can be simultaneously determined in the same assay from one blood sample.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8069655     DOI: 10.1159/000472391

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  4 in total

1.  Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing.

Authors:  A Suomalainen; A C Syvänen
Journal:  Mol Biotechnol       Date:  2000-06       Impact factor: 2.695

2.  Quantification of point mutations associated with Leber hereditary optic neuroretinopathy by solid-phase minisequencing.

Authors:  V Juvonen; K Huoponen; A C Syvänen; E Nikoskelainen; M L Savontaus
Journal:  Hum Genet       Date:  1994-01       Impact factor: 4.132

3.  Solid-phase minisequencing confirmed by FISH analysis in determination of gene copy number.

Authors:  M Laan; K Grön-Virta; A Salo; P Aula; L Peltonen; A Palotie; A C Syvänen
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

4.  Defective respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the tRNA(Leu(UUR)) mutation associated with maternally inherited myopathy and cardiomyopathy.

Authors:  C Mariotti; V Tiranti; F Carrara; B Dallapiccola; S DiDonato; M Zeviani
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.